VYVANSE Drug Patent Profile

Which patents cover Vyvanse, and when can generic versions of Vyvanse launch?

Vyvanse is a drug marketed by Takeda Pharms Usa and is included in two NDAs.

The generic ingredient in VYVANSE is lisdexamfetamine dimesylate. Twenty suppliers are listed for this compound. Additional details are available on the lisdexamfetamine dimesylate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Vyvanse

A generic version of VYVANSE was approved as lisdexamfetamine dimesylate by ACTAVIS ELIZABETH on August 25^th, 2023.

Summary for VYVANSE

US Patents:	0
Applicants:	1
NDAs:	2
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VYVANSE

Paragraph IV (Patent) Challenges for VYVANSE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VYVANSE	Capsules	lisdexamfetamine dimesylate	10 mg	021977	1	2020-04-09
VYVANSE	Capsules	lisdexamfetamine dimesylate	20 mg, 30 mg, 40 mg, 50 mg, 60 mg and 70 mg	021977	6	2011-02-23

US Patents and Regulatory Information for VYVANSE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Takeda Pharms Usa	VYVANSE	lisdexamfetamine dimesylate	CAPSULE;ORAL	021977-007	Oct 30, 2014	AB	RX	Yes	No
Takeda Pharms Usa	VYVANSE	lisdexamfetamine dimesylate	CAPSULE;ORAL	021977-003	Feb 23, 2007	AB	RX	Yes	Yes
Takeda Pharms Usa	VYVANSE	lisdexamfetamine dimesylate	CAPSULE;ORAL	021977-005	Dec 10, 2007	AB	RX	Yes	No

International Patents for VYVANSE

When does loss-of-exclusivity occur for VYVANSE?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Canada

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VYVANSE around the world.

Country	Patent Number	Title	Estimated Expiration
South Korea	20060073538	ABUSE RESISTANT AMPHETAMINE COMPOUNDS
China	1476325	活性物质的输送系统和活性物质的保护和施用方法 (Active agent delivery systems and methods for protecting and administering active agents)
South Korea	100905627

Supplementary Protection Certificates for VYVANSE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1644019	LUC00189	Luxembourg		PRODUCT NAME: LISDEXAMFETAMINE, OPTIONALLY IN THE FORM OF A MESYLATE OR HYDROCHLORIDE SALT THEREOF; AUTHORISATION NUMBER AND DATE: PL08081/0050-52 20200901
1644019	2013/038	Ireland		PRODUCT NAME: LISDEXAMFETAMINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, ESPECIALLY A MESYLATE SALT; NAT REGISTRATION NO/DATE: PA0689/006/001 PA0689/006/002
1644019	549	Finland

VYVANSE (Lisdexamfetamine) Investment Scenario: Market Dynamics, Financial Trajectory, and Strategic Outlook

Last updated: February 3, 2026

Summary

VYVANSE (lisdexamfetamine) stands as a prominent pharmacological option for Attention Deficit Hyperactivity Disorder (ADHD) and Binge Eating Disorder (BED). As a long-acting stimulant prescribed globally, its market presence is shaped by evolving clinical guidelines, regulatory landscapes, and competitive dynamics within the CNS disorder segment. This analysis details VYVANSE's market size, revenue projections, competitive positioning, key market drivers, and associated risks, providing a comprehensive view to stakeholders interested in its investment potential.

---

What Are the Current Market Dynamics for VYVANSE?

Global Market Size and Growth

Parameter	Estimate / Data (2022-2023)	Source
Global ADHD market (2022)	~$20 billion	IQVIA, 2022 Reports
VYVANSE's share in ADHD segment	Approx. 15–20%	IMS Health, 2022
Global BED treatment market	~$1.2 billion (projected to grow at ~8% CAGR through 2027)	MarketWatch, 2022
VYVANSE's approval for BED	USA (since 2017), pending regulatory updates elsewhere	FDA, 2017; EMA status uncertain

Market Penetration and Revenue (2022)

Region	VYVANSE Revenue (USD Millions)	Market Share in ADHD	Notes
North America	~$1.8 billion	~17%	Leading revenue driver
Europe	~$350 million	Limited approval	Growth potential with FDA approval
Asia-Pacific	~$150 million	Low; emerging market	Regulatory and reimbursement hurdles
Rest of World	<$50 million	Minimal	Largely off-label use

Total Approximate Revenue (2022): ~$2.35 billion

---

Market Drivers

• Increasing ADHD diagnosis rates: Estimated to affect 5–7% of children and a significant adult population globally.
• Growing recognition of BED: With increased awareness, demand for pharmacotherapies like VYVANSE gains momentum.
• Extended patent exclusivity: Made possible through new formulations and secondary patents (see below), sustaining revenue streams.

Market Challenges

• Regulatory crackdowns on stimulants: Rising concerns over abuse potential.
• Generic competition: Patent expirations potentially by 2025, threatening revenue erosion.
• Reimbursement policies: Variability across markets; insurance coverage impacts accessibility.

---

Financial Trajectory and Forecasting

Historical Revenue Growth (2018–2022)

Year	Approximate Revenue (USD Millions)	CAGR	Key events
2018	~$1,250	—	FDA approval for VYVANSE for BED
2019	~$1,560	25%	Launch in EU pending approval indication
2020	~$2,020	29%	COVID-19 pandemic impact; increased ADHD diagnoses
2021	~$2.275	12.4%	Expansion to additional markets; product launches
2022	~$2.35 billion	3.3%	Market maturity; patent strategy utilization; price increases

Projected Revenue (2023–2027)

Year	Revenue Estimate (USD Millions)	Growth Rate	Assumptions
2023	~$2.5 billion	6.4%	FDA approval for additional indications; market expansion
2024	~$2.65 billion	6%	Patent exclusivity extended; increased penetration
2025	~$2.8 billion	6%	Potential patent cliff; generic threats mitigation strategies
2026	~$2.9 billion	3.6%	Patent expiration impacts; market share adjustments
2027	~$3.0 billion	~3.4%	Market saturation; new formulations or indications

Note: Revenue projections assume stable demand, regulatory stability, and successful patent strategies. Potential patent expiry risks post-2025 can significantly impact projections.

---

Competitive Landscape and Differentiators

Major Competitors

Drug	Mechanism	Market Share (2022)	Indications	Patent Status
Adderall (Amphetamine + Dextroamphetamine)	Mixed salts stimulant	~50% (US Market)	ADHD, Narcolepsy	Patent expiry (~2023)
Concerta (Methylphenidate)	Extended-release methylphenidate	~20–25%	ADHD	Multiple patents; some expired
Vyvanse (lisdexamfetamine)	Prodrug stimulant designed for longer action	15–20%	ADHD, BED (since 2017)	Patent until ~2025

VYVANSE Differentiators

• Pharmacokinetics: Prodrug with delayed activation reduces abuse potential.
• Extended duration: Up to 14 hours, easing dosing schedules.
• Additional indications: Approved for BED, expanding therapeutic market.

Key Patent Strategies

Patent Type	Period	Protection Scope
Compound patent	Expired (~2025)	Composition of matter for lisdexamfetamine
Method-of-use patents	Extending through new indications	Market exclusivity for BED in US
Formulation patents	Various, until ~2025	Extended protection for delivery methods

---

Regulatory and Policy Environment Impact

Region	Regulatory Status	Impact
US (FDA)	Approved for ADHD, BED	Supportive; potential for new indications in pipeline
Europe	Pending EMA approval for ADHD	Growth potential if approved; current off-label use
Asia-Pacific	Emerging markets; variable policies	Reimbursement and approval hurdles; high growth potential

Policy Trends

• Prescription monitoring programs reducing abuse.
• Reformulations to minimize abuse potential.
• Pricing regulations affecting revenue margins.

---

Comparative Analysis: Investment Considerations

Aspect	VYVANSE	Competitors/Alternatives	Implication for Investors
Market Share	Significant within CNS stimulant segment	Varied; Adderall dominant in US	Market leader in specified segments
Revenue Stability	Moderate; patent protections last until ~2025	High volatility post-patent expiration	Revenue risks increase post-patent expiry
Pharmacological Differentiation	Prodrug with lower abuse potential	Immediate-release compounds	Positioning advantages and clinical differentiation
Indication Breadth	Currently ADHD and BED	Several competitors targeting one indication	Diversification reduces risk
Patent & IP	Multiple patent layers, some expiry imminent	Similar lifecycle for competitors	Strategic patent extensions critical

---

Deep-Dive: Risks and Opportunities

Risks

• Patent Expiry and Generics: Erosion of market share post-2025.
• Regulatory Risks: Stricter controls on stimulant prescriptions.
• Reimbursement Policies: Price controls and formulary restrictions.
• Abuse and Diversion: Increasing societal concerns impacting prescribing.

Opportunities

• Expansion in Europe and Asia: Potential for significant revenue growth.
• New Indications: Off-label uses and approved additional indications.
• Formulation Innovation: Abuse-deterrent formulations and combination therapies.
• Pipeline Development: Research into non-stimulant alternatives.

---

Key Takeaways

• VYVANSE remains a significant revenue generator within the CNS stimulant market, primarily benefiting from its patent protections until approximately 2025.
• The therapeutic market for ADHD and BED continues to grow globally, driven by increasing diagnoses, expanding indications, and favorable regulatory approvals.
• Patent expirations pose substantial risks; strategic patent extensions and formulation innovations are critical to safeguarding revenues.
• Competitive positioning hinges on pharmacological differentiation, market penetration, and regulatory agility.
• Stakeholders should monitor reimbursement trends, regulatory developments, and patent statuses to navigate the evolving landscape effectively.

---

FAQs

Q1: When is VYVANSE's patent expected to expire, and how will that influence its market presence?
A: The primary compound patent for VYVANSE is expected to expire around 2025, potentially opening the market to generic competitors. This could lead to substantial revenue declines unless preventive strategies like formulation patents, new indications, or market expansion are implemented.

Q2: What are the main factors that support VYVANSE’s current market dominance?
A: Its extended-release prodrug design confers a lower abuse potential, favorable dosing profile, and FDA approval for BED, broadening its therapeutic appeal. Patent protections and consistent regulatory approvals also underpin its market position.

Q3: How does VYVANSE compare to competitors like Adderall and Concerta?
A: VYVANSE offers a longer duration of action with a prodrug mechanism, potentially reducing abuse risks. It is marketed as having a lower potential for diversion and aims for improved patient compliance, placing it favorably against immediate-release counterparts.

Q4: What strategies can investors consider to mitigate risks associated with patent expiries?
A: Investors should watch for formulation patent extensions, pipeline developments, entry into emerging markets, and potential new indications that could sustain revenues beyond patent expiration.

Q5: What is the potential impact of regulatory trends on VYVANSE’s future?
A: Stricter controls over stimulant prescriptions could limit access, but positive regulatory environments and approvals for additional indications could bolster its market share. Continuous engagement with regulators and adaptation are essential.

---

References

1. IQVIA. (2022). Global Pharmaceutical Market Data.
2. FDA. (2017). VYVANSE Approval for Binge Eating Disorder.
3. MarketWatch. (2022). Market Size and Trends in BED.
4. IMS Health. (2022). ADHD Market Analysis.
5. European Medicines Agency. (Pending Approval). VYVANSE for ADHD.